



A Meeting of the **Borders Area Drugs and Therapeutics Committee** held at 12:30pm on  
**Wednesday, 24 July 2024 via Microsoft Teams**

**MINUTE**

**Guests:**

Item	Situation; Background; Assessment	Recommendation	Lead	Timescale
1.	<p><b>Welcome and Announcements:</b>  <b>Present:</b> Malcolm Clubb, Director of Pharmacy (MC); Cathryn Park, Senior Clinical Pharmacist (CP); Dr Nicola Henderson, GP; Kirsten Thomson, Clinical Pharmacist (KT); Keith Maclure, Lead Pharmacist (KMacl); Rhona Morrison, Medicines Governance/NMP Lead (RM); Kate Warner, Meeting Administrator (KW).   <b>Apologies:</b> Dr Rebecca Devine, Consultant in Public Health; Andrew Leitch, Lay-member; Dr Kevin Buchan, GP (Malcolm Clubb to Chair); Dr Ed James, Consultant Microbiologist (EJ); Dr Effie Dearden, DME Consultant (ED).</p>			
2.	<b>Declarations of Interest:</b>			
3.	<b>DRAFT Minute previous meeting</b>			
3.1	Draft minute from 22 May 2024 meeting was approved as an accurate record of the meeting with no changes.	Remove draft; upload to internet	KW	25/07/2024
4.	<b>Matters Arising</b>			
4.1	Policy - Management of Hyperkalaemia in Adults – changes made requested by ADTC were updated. KT liaised with author. The 50% glucose was questioned as this should only be given by a central line and a more diluted glucose was suggested. Medical staff consensus was to proceed with it at 50%.	ADTC Approved Email to absent members then email to author if fully approved.	KW	31/07/2024
4.2	Guideline for Insulin Adjustment by Diabetes Specialist Dietitians – changes made with pharmacy input requested by ADTC. KT has reviewed and updated with dieticians. This is not a PGD and that has been made clear; outdated quotes have been removed and responsibility tightened up; altering	ADTC Approved Email to absent members then	KW	31/07/2024

	insulin is clear what can be done; moved roles and responsibilities to top of document. A typo was pointed out on page 6 which? To be corrected by author.	email to author if fully approved.		
<b>5.</b>	<b>NEW MEDICINE APPLICATIONS / NON-FORMULARY REQUESTS:</b>			
5.1	ADTC noted the NFR Panel decisions made since last ADTC meeting: Approved – Lefunomide; Mepacrine; Fluvoxamine. Not Approved – Sativex; Riboflavin; Tirzepatide. Further information was received and Sativex application was approved at the following NFR meeting with clear criteria and conditions for a short period of treatment. Tirzepatide was not approved based on forthcoming East Region Formulary submission.	ADTC Noted Update NFR spreadsheet	KW	31/07/2024
<b>6.</b>	<b>PATIENT &amp; MEDICINES SAFETY:</b>			
6.1	ADTC noted the Patient and Medicines Safety Update – Datix Medication Error report May - July 2024 A couple of majors were highlighted that are to be reviewed. KT commented on the pressure on the Pharmacy team regarding supply issues and how skilled the staff are in this. Grading is listed in Datix order and ADTC asked for the report to be ordered in grading for the next meeting.	ADTC Noted Change order of grading for next report	RM	16/09/2024
<b>7.</b>	<b>CLINICAL POLICIES, PROCEDURES and GUIDELINES for APPROVAL:</b>			
7.1	Alcohol Detox Guidelines from Dr Niall Campbell; ADTC reviewed, and comments were made regarding the order and layout which could be confusing and easy to miss important points unless you read the whole document. Summary at beginning is important but would be easy to read just that and miss other points. Scoring at the end of the policy was highlighted as this should be printed and made available on the wards; it should also be available through clinical documentation to order. Some safety issues were raised that require checking, Pabrinex changes could be included in as update and some areas would benefit from further review. ADTC asked KT and MC to meet with Dr Campbell to update and take to clinical documentation group regarding stationery. To come back to ADTC for approval when updated.	Not Approved Email to author Meet with Dr Campbell re update. Request RDS template to use for update. Sep ADTC	KW KT and MC KW  KW	31/07/2024 31/07/2024  24/07/2024  16/09/2024
7.2	Update to Enteral Feed for Adults Guideline, authored by Dr Jonathan Manning and Lynne Cairns, Acute Lead Dietitian was discussed by ADTC. There has been a change to appendix 8 in ward monitoring. There was no overview of the changes that had been made and the policy is significantly reduced in size. ADTC asked that JM and LC attend the September ADTC meeting to discuss the policy and its changes in full.	Not Approved Email authors Sep ADTC	KW KW	31/07/2024 16/09/2024
7.3	Updated Paper – Items of Low Clinical Value, was tabled for approval before going to the Board (Board cover paper with paper as appendix attached) EJ had sent a comment regarding Minocycline in ‘items not to be prescribed’. It indicates in the comment that this refers to its use in acne; there are some specific pathogens (outside of acne) for which minocycline is one of the few available treatments and in some other infections it may be preferred over other tetracyclines. KMacl commented that this would be only used in consultation with Consultant Microbiologist and would be non-formulary request for use. ADTC agreed that the wording should be changed to reflect that. ADTC heard that Scottish Government are expected to also bring out a strong message	ADTC Approved Email to absent members then email to author if fully approved.	KW	31/07/2024

	on items of low clinical value and asked that the Board send communications to all prescribers. It was agreed that the information should be disseminated to the public, patients and staff carefully. The messaging will also be shared with elected MP and MSP to ensure they are aware in anticipation of patient letters/complaints. The list mirrors Department of Health England list from 2017 and will be going to GP Sub meeting next week for discussion and approval.			
<b>8.</b>	<b>FOR INFORMATION and NOTING:</b>			
8.1	ADTC noted the Yellow Card Scotland Annual Report for 2022/23; numbers have increased over the period. It was agreed that communications should go out to encourage filling out the yellow card for all Borders colleagues. This important task is often overlooked, and prescribers may only complete when it is a new drug for prescription. ADTC agreed that clear reminder communication is necessary to re-emphasise the importance of completing yellow cards. It was also agreed that communications should go out as a reminder of the roles of groups, such as ADTC as there is a lack of understanding of the remit of groups and work may be being duplicated at meetings.	ADTC Noted Discuss with comms how to disseminate and educate	RM	30/08/2024
8.2	ADTC noted the consensus guidance developed by the Scottish Diabetes Group to provide national criteria to support the use of GLP-1/GIP receptor agonists (RAs) for the treatment of type 2 diabetes in NHS Scotland. The aim of this work is to support NHS Scotland in the implementation of Scottish Medicine Consortium (SMC) advice for the use of this medicine for the treatment of type 2 diabetes.	ADTC Noted		
8.3	ADTC discussed the Pharmacy Alert for Topiramate (Topamax) and asked that this be disseminated appropriately throughout the organisation. It was agreed that ADTC should write to Neurology and other specialities who use this routinely and ask for them to respond with their plans are for pregnancy prevention. The letter will ask for assurance that they have reviewing and actioned the information. Inclusion in and changes to the Pharmacy Annual Report for next year were mentioned.	ADTC Noted Letter to specialities using Topiramate	MC and KT	30/08/2024
<b>9.</b>	<b>FEEDBACK from SUBGROUPS</b>			
9.1	Anticoagulation Committee meeting – next meeting September 2024; there has been a lack of meeting attendance and RM has asked AMDs who would attend; requesting nominations. There has been no response and RM will follow up. A new Haematologist joining NHS Borders in September will be asked to attend. It was suggested that locums and/or fellows may be interested in attending – if this is appropriate to the committee.	ADTC Noted Follow up on membership	RM	30/08/2024
9.2	Antimicrobial Management Team action tracker – April 2024 meeting	ADTC Noted		
9.3	IV Therapy Group notes from meeting held 8 May 2024 – not available. RM highlighted that there has been a change at Kelso and Knoll Community Hospitals which are now ANP-led rather than GP-led. Medication will be available by nurses as a prescriber will be onsite. This is in the early stages, and they are looking at what can be done moving forward. RM is discussing nurse prescriber and ANPs being able to do IVs which would stop patients having to come to BGH and could be managed in community hospitals. NH commented that if this could be done in patients	ADTC Noted		

	homes they could stop using community hospitals.			
9.4	Medicines Resource Group – next meeting 24 July 2024			
9.5	Medicines Governance and Safety Group – no recent minute/meeting; next meeting 20 <sup>th</sup> August.			
9.6	Tissue Viability Steering Group – no recent minute/meeting. ADTC discussed the dressings project meetings and tissue viability. A stock list for district nurses has been a successful piece of work and it is hoped this can also be produced for other groups. Formulary is being updated and RM will be meeting with TV QI as soon as possible to follow up.	ADTC Noted Meeting with TV QI	RM	30/08/2024
9.7	East Region Formulary Committee minute from meeting held 29 May 2024 was noted by ADTC and the Stop and Assess pre-ERFC meeting was discussed; this is attended by KT and Medical Director. Most applications are from Lothian and this meeting is an additional check on the applications before they go to ERFC meeting.	ADTC Noted Discuss comms with clinical staff with Medical Director	MC	30/08/2024
9.8	NHS Lothian ADTC minute from meeting held 5 April 2024	ADTC Noted		
<b>10.</b>	<b>AOCB</b>			
10.1	Request for membership for National Review Panel for PACS Tier 2; check members from last year. KMacl and MC can attend.	ADTC Members to be nominated	MC	06/08/2024
<b>Date and time of next meeting: Wednesday 25 September 2024 at 12:30pm via Microsoft Teams.</b>				
<b>Items expected for future Agendas –</b> SEPTEMBER 2024 – <b>Patient Group Directions Audit</b> (KW/RM) FUTURE 2024 <b>NHS Borders Guideline on NHS Care and Private Treatment</b> (Rebecca Devine/Dr Sohail Bhatti)				
<b>September 2024 - PRESENTATION</b> – To further strengthen the links between SMC and Health Boards, Dr Scott Muir, SMC Chair and Dr Yvonne Semple, Chief Pharmaceutical Adviser are planning to visit ADTCs around Scotland to update committees on the work of SMC, enable discussion around issues of common interest and receive feedback on how SMC can further collaborate with ADTCs.				